← GeneDx Holdings Corp.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $196.2m |
$179.3m
-8.59%
|
$212.2m
+18.33%
|
$234.7m
+10.60%
|
$202.6m
-13.69%
|
$305.4m
+50.79%
|
$427.5m
+39.97%
|
$454.4m
+6.29%
|
|
| Cost of services | $113.4m |
$175.3m
+54.60%
|
$228.8m
+30.52%
|
$261.4m
+14.27%
|
$112.6m
-56.95%
|
$111.1m
-1.34%
|
$129.4m
+16.49%
|
— | |
| Gross profit | $82.8m |
$4.0m
-95.14%
|
($16.6m)
-512.37%
|
($26.8m)
-61.13%
|
$90.0m
+436.47%
|
$194.4m
+115.98%
|
$298.2m
+53.38%
|
$315.2m
+5.73%
|
|
| Research and development | $34.9m | $72.7m | $105.2m | $86.2m | $58.3m | $45.7m | $72.0m | $83.8m | |
| Selling and marketing | $39.4m | $63.2m | $112.7m | $134.9m | $61.0m | $67.4m | $88.4m | $290.0m | |
| General and administrative | $29.5m | $206k | $206.0m | $203.3m | $133.8m | $101.1m | $150.8m | $201.6m | |
| Other operating expenses, net | — | — | — | $6.3m | $7.2m | $3.4m | $0 | — | |
| Loss from operations | ($30.4m) |
($206k)
+99.32%
|
($446.1m)
-216272.37%
|
($667.7m)
-49.65%
|
($180.6m)
+72.95%
|
($23.2m)
+87.15%
|
($13.1m)
+43.67%
|
— | |
| Total non-operating (expense) income, net | $709k | $654k | $200.8m | $69.6m | $3.9m | ($29.4m) | ($8.1m) | — | |
| Loss before income taxes | ($29.7m) | ($192k) | ($245.4m) | ($598.0m) | ($176.7m) | ($52.6m) | ($21.1m) | — | |
| Income tax benefit | $0 | $0 | $0 | $49.1m | $926k | $343k | $116k | — | |
| Net loss | ($29.7m) | ($192k) | ($245.4m) | ($549.0m) | ($175.8m) | ($52.3m) | ($21.0m) | — | |
| Basic net loss per share, Class A common stock (in dollars per share) | ($264k) | ($47k) | ($2) | ($2) | ($7) | ($2) | ($1) | — | |
| Diluted net loss per share, Class A common stock (in dollars per share) | ($264k) | ($47k) | ($2) | ($2) | ($7) | ($2) | ($1) | — | |
| Basic weighted average shares outstanding of Class A common stock (in shares) | 124 | 5k | 108.1m | 337.8m | 24.3m | 26.9m | 28.6m | — | |
| Diluted weighted average shares outstanding of Class A common stock (in shares) | 124 | 5k | 108.1m | 337.8m | 24.3m | 26.9m | 28.6m | — | |
| Impairment loss | — | $0 | $0 | $210.1m | $10.4m | $0 | $0 | — | |
| Change in fair value of financial liabilities | — | — | — | — | $1.2m | ($13.4m) | ($1.2m) | — | |
| Interest (expense) income, net | — | — | — | — | $1.1m | ($3.0m) | ($2.5m) | $3.1m | |
| Other (expense) income, net | $504k | $2.6m | $5.1m | $57k | $1.6m | ($13.0m) | ($4.3m) | — | |
| Unrealized gain related to available for sale securities, net | — | — | — | $0 | $425k | $405k | $106k | — | |
| Comprehensive loss | ($29.7m) | ($241.3m) | ($245.4m) | ($549.0m) | ($175.3m) | ($51.9m) | ($20.9m) | — |